Description
P18 Early discontinuation of lenalidomide in patients with relapsing or refractory multiple myeloma: predictive factors for stopping in the real life
Article: P18 Early discontinuation of lenalidomide in patients with relapsing or refractory multiple myeloma: predictive factors for stopping in the real life
€3.03
Related products
-
Article: Highlights in respiratory oncology
€3.03 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart -
1 year access Online Belgian Journal of Hematology (BJH)
€71.94 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart
Reviews
There are no reviews yet.